InteRNA, Cenix Ink miRNA Deal | GenomeWeb
NEW YORK (GenomeWeb News) – Dutch firm InteRNA Technologies and German firm Cenix BioScience today said that they will collaborate on screening assays for miRNAs and therapeutic targets for cancer.
 
Cenix will use InteRNA’s lentiviral-based miRNA overexpression library in high-throughput screening assays in combination with high-content, multi-parametric phenotypic analyses to determine the biological role of individual miRNAs and to identify cancer drug targets.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.